Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer
Dudzinski, Stephanie O.
Cameron, Brent D.
Rathmell, Jeffrey C.
Giorgio, Todd D.
Kirschner, Austin N.
Background Prostate cancer is poorly responsive to immune checkpoint inhibition, yet a combination with radiotherapy may enhance the immune response. In this study, we combined radiotherapy with immune checkpoint inhibition (iRT) in a castration-resistant prostate cancer (CRPC) preclinical model. Methods Two Myc-CaP tumor grafts were established in each castrated FVB mouse. Anti-PD-1 or anti-PD-L1 antibodies were given and one graft was irradiated 20 Gy in 2 fractions. Results In CRPC, a significant increase in survival was found for radiation treatment combined with either anti-PD-1 or anti-PD-L1 compared to monotherapy. The median survival for anti-PD-L1 alone was 13 days compared to 30 days for iRT (p = 0.0003), and for anti-PD-1 alone was 21 days compared to 36 days for iRT (p = 0.0009). Additional treatment with anti-CD8 antibody blocked the survival effect. An abscopal treatment effect was observed for iRT in which the unirradiated graft responded similarly to the irradiated graft in the same mouse. At 21 days, the mean graft volume for anti-PD-1 alone was 2094 mm(3) compared to iRT irradiated grafts 726 mm(3) (p = 0.04) and unirradiated grafts 343 mm(3) (p = 0.0066). At 17 days, the mean graft volume for anti-PD-L1 alone was 1754 mm(3) compared to iRT irradiated grafts 284 mm(3) (p = 0.04) and unirradiated grafts 556 mm(3) (p = 0.21). Flow cytometry and immunohistochemistry identified CD8+ immune cell populations altered by combination treatment in grafts harvested at the peak effect of immunotherapy, 2-3 weeks after starting treatment. Conclusions These data provide preclinical evidence for the use of iRT targeting PD-1 and PD-L1 in the treatment of CRPC. Immune checkpoint inhibition combined with radiotherapy treats CPRC with significant increases in median survival compared to drug alone: 70% longer for anti-PD-1 and 130% for anti-PD-L1, and with an abscopal treatment effect. Precis Castration-resistant prostate cancer in a wild-type mouse model is successfully treated by X-ray radiotherapy combined with PD-1 or PD-L1 immune checkpoint inhibition, demonstrating significantly increased median overall survival and robust local and abscopal treatment responses, in part mediated by CD8 T-cells.
This item appears in the following collection(s):
Showing items related by title, author, creator and subject.
Shu, Xiao-Ou; Zheng, Wei (AMERICAN JOURNAL OF EPIDEMIOLOGY, 2019-06)The Consortium of Metabolomics Studies (COMETS) was established in 2014 to facilitate large-scale collaborative research on the human metabolome and its relationship with disease etiology, diagnosis, and prognosis. COMETS ...
The impact of delay: assessing the early indicators of development time and accrual milestones on oncology clinical trial success Cheng, Steven Kunyuan (2008-12-22)This research discovers if there are early indicators of the conduct of clinical trials that related to predicting the success of a clinical trial. Successful trials were those achieving at least 100% of the minimum ...
What Caused My Cancer? Cancer Patients' Perceptions on What May Have Contributed to the Development of Their Cancer: A Cross-Sectional, Cross-Country Comparison Study Hall, Alix; Nguyen, Sang Minh; Mackenzie, Lisa; Sanson-Fisher, Rob; Olver, Ian; Thuan, Tran Van; Huong, Tran Thanh (CANCER CONTROL, 2019-07-23)Accurate public perceptions on the risk factors associated with cancer are important in promoting primary, secondary, and tertiary prevention. Limited studies have explored this topic among patients with cancer in non-western, ...